Autosomal Dominant Polycystic Kidney Disease: 2009 Update for Internists

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2009 Sep 2

PMID 19721850

Citations 8

Authors

William M Bennett

Affiliations

Soon will be listed here.

Abstract

Because autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic abnormalities seen in today's medical practice, many internists will likely treat patients affected by this condition. Genetic abnormalities have been increasingly recognized, and the pathophysiology of the disease is beginning to be unraveled. Because of advances in imaging technology, surrogate markers for disease progression have allowed clinical studies of newer therapeutic agents to proceed. In the near future, therapies for this common genetic disease may be available to either prevent or stabilize the disease course for many affected individuals.

Citing Articles

Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease.

Oberdhan D, Cole J, Atkinson M, Krasa H, Davison S, Perrone R Clin J Am Soc Nephrol. 2023; 18(2):213-222.

PMID: 36754008 PMC: 10103266. DOI: 10.2215/CJN.0000000000000034.

Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period.

Huh H, Kim Y, Chung W, Kim Y, Kim Y, Han S Kidney Res Clin Pract. 2023; 42(2):216-228.

PMID: 36634967 PMC: 10085719. DOI: 10.23876/j.krcp.22.024.

Prevalence, risk factors and disease knowledge of polycystic kidney disease in Pakistan.

Zahid R, Akram M, Rafique E Int J Immunopathol Pharmacol. 2020; 34:2058738420966083.

PMID: 33125856 PMC: 7607775. DOI: 10.1177/2058738420966083.

Examining the Role of Polymorphisms in Exon 25 of the Gene in the Pathogenesis of Autosomal Dominant Polycystic Kidney Disease in ranian Patients.

Bagheri M, Makhdoomi K, Taghizadeh Afshari A, Nikibakhsh A, Abdi Rad I Rep Biochem Mol Biol. 2019; 8(2):102-110.

PMID: 31832432 PMC: 6844614.

A comparison of the effects of losartan and ramipril on blood pressure, renal volume and progression in polycystic kidney disease: A 5-Year follow-up.

Ulusoy S, Ozkan G, Kosucu P, Kaynar K, Eyuboglu I Hippokratia. 2013; 16(2):143-8.

PMID: 23935270 PMC: 3738416.

References

Torres V, Harris P, Pirson Y . Autosomal dominant polycystic kidney disease. Lancet. 2007; 369(9569):1287-1301. DOI: 10.1016/S0140-6736(07)60601-1. View

Pei Y, Obaji J, Dupuis A, Paterson A, Magistroni R, Dicks E . Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2008; 20(1):205-12. PMC: 2615723. DOI: 10.1681/ASN.2008050507. View

Patel V, Chowdhury R, Igarashi P . Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens. 2009; 18(2):99-106. PMC: 2820272. DOI: 10.1097/MNH.0b013e3283262ab0. View

Huang E, Samaniego-Picota M, McCune T, Melancon J, Montgomery R, Ugarte R . DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease. Transplantation. 2009; 87(1):133-7. PMC: 2841023. DOI: 10.1097/TP.0b013e318191e729. View

Grantham J, Cook L, Torres V, Bost J, Chapman A, Harris P . Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 2007; 73(1):108-16. PMC: 2790405. DOI: 10.1038/sj.ki.5002624. View

Grantham J, Torres V, Chapman A, Guay-Woodford L, Bae K, King Jr B . Volume progression in polycystic kidney disease. N Engl J Med. 2006; 354(20):2122-30. DOI: 10.1056/NEJMoa054341. View

Pei Y . A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease?. Trends Mol Med. 2001; 7(4):151-6. DOI: 10.1016/s1471-4914(01)01953-0. View

Harris P, Bae K, Rossetti S, Torres V, Grantham J, Chapman A . Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006; 17(11):3013-9. DOI: 10.1681/ASN.2006080835. View

Steinman T . Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2007; 23(2):431-3. DOI: 10.1093/ndt/gfm865. View

10.

Ecder T, Schrier R . Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009; 5(4):221-8. PMC: 2720315. DOI: 10.1038/nrneph.2009.13. View

11.

Nauli S, Alenghat F, Luo Y, Williams E, Vassilev P, Li X . Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003; 33(2):129-37. DOI: 10.1038/ng1076. View

12.

Rossetti S, Kubly V, Consugar M, Hopp K, Roy S, Horsley S . Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009; 75(8):848-55. PMC: 2813773. DOI: 10.1038/ki.2008.686. View

13.

Wilson P . Polycystic kidney disease. N Engl J Med. 2004; 350(2):151-64. DOI: 10.1056/NEJMra022161. View

14.

Rossetti S, Consugar M, Chapman A, Torres V, Guay-Woodford L, Grantham J . Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007; 18(7):2143-60. DOI: 10.1681/ASN.2006121387. View

15.

Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L . Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol. 1996; 7(10):2142-51. DOI: 10.1681/ASN.V7102142. View

16.

Chapman A . Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008; 3(4):1197-204. DOI: 10.2215/CJN.00060108. View

17.

Elzinga L, Golper T, Rashad A, Carr M, Bennett W . Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int. 1987; 32(6):884-8. DOI: 10.1038/ki.1987.290. View

18.

Elzinga L, Golper T, Rashad A, Carr M, Bennett W . Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother. 1988; 32(6):844-7. PMC: 172293. DOI: 10.1128/AAC.32.6.844. View

19.

Grantham J . Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008; 359(14):1477-85. DOI: 10.1056/NEJMcp0804458. View